Management of Seizures in Patients with FSGS

Understanding the Clinical Context

• Seizures in FSGS patients typically arise from metabolic derangements related to nephrotic syndrome, such as severe hyponatremia, hypocalcemia, and hypomagnesemia, as recommended by the American Journal of Kidney Diseases 1, 2
• Hypertensive encephalopathy from uncontrolled blood pressure in the setting of kidney disease is another cause of seizures, according to the American Journal of Kidney Diseases and Kidney International 2, 3
• Drug toxicity from calcineurin inhibitors, such as cyclosporine or tacrolimus, can cause neurotoxicity and lower seizure threshold, as reported by Kidney International 4, 5

Immediate Seizure Management Algorithm

• Obtain immediate serum electrolytes, glucose, and renal function to identify the cause of seizures, as recommended by the American Journal of Kidney Diseases 1, 2
• Measure blood pressure urgently to exclude hypertensive emergency, according to the American Journal of Kidney Diseases and Kidney International 2, 3
• Use benzodiazepines, such as lorazepam or diazepam, for acute seizure termination, with dose adjustment for renal function, as recommended by the American Journal of Kidney Diseases 1
• Initiate maintenance anticonvulsant therapy based on standard neurological protocols, selecting agents with minimal renal excretion if kidney function is impaired, according to the American Journal of Kidney Diseases 2

Adjusting FSGS Treatment in Context of Seizures

• High-dose corticosteroids may worsen seizure control through electrolyte disturbances, as reported by Kidney International 3
• Target lower cyclosporine trough levels or tacrolimus levels if neurotoxicity is suspected, as recommended by Kidney International 3, 4, 5
• Consider switching from cyclosporine to alternative agents if seizures persist despite dose reduction, although this is not explicitly cited in the provided references

Critical Monitoring Parameters

• Weekly electrolytes during the first month of immunosuppression, then monthly, as recommended by the American Journal of Kidney Diseases 1, 2
• Blood pressure monitoring at every visit, targeting ≤125/80 mmHg with ACE inhibitor or ARB at maximally tolerated dose, according to Kidney International and Praxis Medical Insights 3, 6
• CNI trough levels every 2 weeks initially, then monthly once stable, as reported by Kidney International 4, 5
• Neurological examination at each follow-up to detect early signs of encephalopathy, as recommended by Kidney International 3

Common Pitfalls to Avoid

• Do not attribute all seizures to FSGS itself, and do not continue full-dose CNIs if neurotoxicity is suspected, as reported by Kidney International 4, 5
• Do not correct hyponatremia rapidly in nephrotic patients on diuretics, as this causes more harm than the hyponatremia itself, according to the American Journal of Kidney Diseases 1, 2